Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:20
|
作者
Weissfeld, JL
Fagerstrom, RM
O'Brien, B
机构
[1] NCI, Div Canc Prevent, Biometry Res Grp, Bethesda, MD 20892 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Westat Inc, Rockville, MD USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 06期
关键词
quality control; cancer screening; procedures; data analysis;
D O I
10.1016/S0197-2456(00)00094-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Investigators for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial describe quality control procedures for the digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, and flexible sigmoidoscopy. These cancer screening tests are subjective and difficult to standardize. PLCO quality control procedures aim to measure and, where possible, reduce variation, across examiner and screening center, with respect to cancer screening test performance. Initial protocols stressed examiner qualifications, experience, and training; equipment specifications; examination procedures; and definitions for positive tests. The PLCO quality assurance subcommittee developed a final quality assurance plan, which included central approval and registration of PLCO examiners, direct observation of screening test performance during periodic site visits by the National Cancer Institute and coordinating center auditors, periodic analysis of screening test data, and procedures for independently duplicating or reviewing selected examinations. For each modality, the periodic data analyses examine the test-positive and the test-inadequate proportions and aim to identify divergent centers or examiners. Procedures for duplicating examinations specify feasible sample sizes for precise estimates of agreement between examiners, at each center, for each screening test modality, and over a 1-year period. These quality control procedures will help characterize the consistency and reliability of the PLCO cancer screening tests. Control Clin Trials 2000;21:390S-399S (C) Elsevier Science Inc. 2000.
引用
收藏
页码:390S / 399S
页数:10
相关论文
共 50 条
  • [1] The Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial: status and promise
    Andriole, GL
    Reding, D
    Hayes, RB
    Prorok, PC
    Gohagan, JK
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) : 358 - 361
  • [2] Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first six years
    Simpson, NK
    Johnson, CC
    Ogden, SL
    Gamito, E
    Trocky, N
    McGuire, C
    Martin, J
    Barrow, S
    Lamerato, L
    Flickinger, LM
    Broski, KG
    Engelhard, D
    Hilke, C
    Bonk, J
    Gahagan, B
    Gren, LH
    Childs, J
    Lappe, K
    Fouad, M
    Thompson, J
    Sullivan, D
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 356S - 378S
  • [3] Lethal Prostate Cancer in the PLCO Cancer Screening Trial
    Shoag, Jonathan
    Mittal, Sameer
    Halpern, Joshua A.
    Scherr, Douglas
    Hu, Jim C.
    Barbieri, Christopher E.
    EUROPEAN UROLOGY, 2016, 70 (01) : 2 - 5
  • [4] Cancer Screening in the Elderly A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening
    Kotwal, Ashwin A.
    Schonberg, Mara A.
    CANCER JOURNAL, 2017, 23 (04) : 246 - 253
  • [5] Building Successful Relationships in the PLCO Cancer Screening Trial
    Marcus, Pamela M.
    Broski, Karen G.
    Buys, Saundra S.
    Childs, Jeffery
    Church, Timothy R.
    Gohagan, John K.
    Gren, Lisa H.
    Higgins, Darlene
    Jaggi, Rachel
    Jenkins, Victoria
    Johnson, Christine C.
    Lappe, Karen
    O'Brien, Barbara
    Ogden, Sheryl L.
    Prorok, Philip C.
    Reding, Douglas
    Shambaugh, Vicki
    Yokochi, Lance A.
    Yurgalevitch, Susan
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (03) : 181 - 186
  • [6] Colorectal cancer screening completion: An examination of differences by screening modality
    Rutten, Lila J. Finney
    Jacobson, Debra J.
    Jenkins, Gregory D.
    Fan, Chun
    Weiser, Emily
    Parks, Philip
    Doroshenk, Mary
    Limburg, Paul J.
    St Sauver, Jennifer L.
    PREVENTIVE MEDICINE REPORTS, 2020, 20
  • [7] Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival
    Temkin, Sarah M.
    Miller, Eric A.
    Samimi, Goli
    Berg, Christine D.
    Pinsky, Paul
    Minasian, Lori
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 182 - 188
  • [8] Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women's Health Initiativey
    You, Dongfang
    Zhang, Mingzhi
    He, Wenjing
    Wang, Danhua
    Yu, Yang
    Yu, Zhaolei
    Lange, Theis
    Yang, Sheng
    Wei, Yongyue
    Ma, Hongxia
    Hu, Zhibin
    Shen, Hongbing
    Chen, Feng
    Zhao, Yang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 45 - +
  • [9] Continuous quality improvement of colorectal cancer screening
    Mariusz Madalinski
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2013, (01) : 1 - 3
  • [10] Screening for prostate cancer: growth without control
    Eisinger, Francois
    Blay, Jean-Yves
    Pivot, Xavier
    Morere, Jean-Francois
    Coscas, Yvan
    Calazel-Benque, Anne
    Roussel, Claire
    Viguier, Jerome
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2011, 20 : S33 - S35